TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$4.81 +0.01 (+0.21%) As of 03:09 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About HLS Therapeutics Stock (TSE:HLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HLS Therapeutics alerts:Sign Up Key Stats Today's RangeC$4.73▼C$4.8450-Day RangeC$4.17▼C$5.0552-Week RangeC$3.00▼C$5.23Volume6,443 shsAverage Volume13,582 shsMarket CapitalizationC$107.01 millionP/E RatioN/ADividend Yield4.16%Price TargetC$4.50Consensus RatingHold Company Overview HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world. Read More HLS Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreHLS MarketRank™: HLS Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingHLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHLS Therapeutics has received no research coverage in the past 90 days.Read more about HLS Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HLS. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipHLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth.Read more about HLS Therapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for HLS. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for HLS Therapeutics this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$495.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 0.37% of the stock of HLS Therapeutics is held by insiders.Percentage Held by Institutions65.20% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HLS Therapeutics' insider trading history. Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HLS Stock News HeadlinesHLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug PlanJuly 2 at 9:56 AM | finance.yahoo.comHLS Therapeutics Reports Annual Meeting ResultsJune 20, 2025 | finance.yahoo.comBanks aren’t ready for this altcoin—are you?Want to see why we believe this could be the next evolution of financial infrastructure? The old financial system is showing cracks—and this altcoin might be ready to take its placeJuly 2 at 2:00 AM | Crypto 101 Media (Ad)The past five years for HLS Therapeutics (TSE:HLS) investors has not been profitableJune 20, 2025 | finance.yahoo.comHLS Therapeutics First Quarter 2025 Earnings: EPS Misses ExpectationsMay 10, 2025 | finance.yahoo.comEarnings call transcript: HLS Therapeutics Q1 2025 results show mixed signalsMay 10, 2025 | uk.investing.comHLS Therapeutics Announces Q1 2025 Financial ResultsMay 10, 2025 | seekingalpha.comHLS Therapeutics Inc (HLS) Receives a Hold from Stifel NicolausMarch 14, 2025 | markets.businessinsider.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$3.93 at the start of the year. Since then, HLS stock has increased by 22.4% and is now trading at C$4.81. View the best growth stocks for 2025 here. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. HLS Therapeutics had a negative trailing twelve-month return on equity of 25.27% and a negative net margin of 38.70%. Read the conference call transcript. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV). Company Calendar Last Earnings11/07/2024Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price TargetC$4.50 High Stock Price TargetC$5.00 Low Stock Price TargetC$4.00 Potential Upside/Downside-7.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$15.53 million Net Margins-38.70% Pretax MarginN/A Return on Equity-25.27% Return on Assets-2.89% Debt Debt-to-Equity Ratio86.50 Current Ratio1.56 Quick Ratio1.01 Sales & Book Value Annual SalesC$40.13 million Price / Sales2.68 Cash FlowC$0.32 per share Price / Cash Flow15.22 Book ValueC$2.51 per share Price / Book1.93Miscellaneous Outstanding Shares22,247,717Free FloatN/AMarket CapC$107.68 million OptionableNot Optionable Beta1.07 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (TSE:HLS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.